← Back to Search

Wee1 Inhibitor

AZD6738 for Cancer (OLAPCO Trial)

Phase 2
Waitlist Available
Led By Joseph P Eder, MD
Research Sponsored by Joseph Paul Eder
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 16 weeks
Awards & highlights

OLAPCO Trial Summary

This trial is testing a new treatment to see if it is effective against cancer. The study will compare how well the treatment works before and after 16 weeks of treatment.

OLAPCO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate

OLAPCO Trial Design

4Treatment groups
Experimental Treatment
Group I: Group 4Experimental Treatment2 Interventions
Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
Group II: Group 3Experimental Treatment2 Interventions
Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
Group III: Group 2Experimental Treatment2 Interventions
Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
Group IV: Group 1Experimental Treatment1 Intervention
Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ceralasertib
Not yet FDA approved
Capivasertib
Not yet FDA approved
MK-1775
Not yet FDA approved
Olaparib
FDA approved

Find a Location

Who is running the clinical trial?

Vanderbilt-Ingram Cancer CenterOTHER
213 Previous Clinical Trials
60,866 Total Patients Enrolled
Joseph Paul EderLead Sponsor
The Cleveland ClinicOTHER
1,027 Previous Clinical Trials
1,364,211 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
OLAParib COmbinations
Joseph Paul Eder 2015. "OLAParib COmbinations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02576444.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top